{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:10:45Z","timestamp":1785514245391,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T00:00:00Z","timestamp":1515801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11060-018-2752-5","type":"journal-article","created":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T03:07:31Z","timestamp":1515812851000},"page":"601-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Neurologic complications of immune checkpoint inhibitors"],"prefix":"10.1007","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-9134","authenticated-orcid":false,"given":"Avi","family":"Fellner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Makranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Lotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bokstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Taliansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah T.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Fichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Kogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit","family":"Yust-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,13]]},"reference":[{"key":"2752_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","volume":"54","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, Powles T, Vogelzang NJ (2017) A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev 54:58\u201367","journal-title":"Cancer Treat Rev"},{"key":"2752_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138","journal-title":"Eur J Cancer"},{"key":"2752_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11060-017-2390-3","volume":"132","author":"M Sinnadurai","year":"2017","unstructured":"Sinnadurai M, McDonald KL (2017) Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. J Neurooncol 132:359\u2013372","journal-title":"J Neurooncol"},{"issue":"2 Pt A","key":"2752_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.molimm.2015.02.009","volume":"67","author":"A Swaika","year":"2015","unstructured":"Swaika A, Hammond WA, Joseph RW (2015) Current state of anti-PD-L1 and anti-PD1 agents in cancer therapy. Mol Immunol 67(2 Pt A):4\u201317","journal-title":"Mol Immunol"},{"key":"2752_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitors. Front Pharmacol 8:49. \n                    https:\/\/doi.org\/10.3389\/fphar.2017.00049","journal-title":"Front Pharmacol"},{"issue":"6","key":"2752_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","volume":"29","author":"AF Hottinger","year":"2016","unstructured":"Hottinger AF (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29(6):806\u2013812","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"2752_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J et al (2017) Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolmab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22(6):709\u2013718","journal-title":"Oncologist"},{"issue":"4","key":"2752_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology 16(4):589\u2013593","journal-title":"Neuro-Oncology"},{"issue":"2","key":"2752_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","volume":"27","author":"BH Nguyen","year":"2017","unstructured":"Nguyen BH, Kuo J, Budiman A, Christie H, Ali S (2017) Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res 27(2):152\u2013154","journal-title":"Melanoma Res"},{"issue":"12","key":"2752_CR10","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/S1470-2045(16)30571-X","volume":"17","author":"W Wick","year":"2016","unstructured":"Wick W, Hertenstein A, Platten M (2016) Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 17(12):e529\u2013e541","journal-title":"Lancet Oncol"},{"key":"2752_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210\u2013225","journal-title":"Eur J Cancer"},{"issue":"10","key":"2752_CR12","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216\u20131222","journal-title":"JAMA Neurol"},{"issue":"3","key":"2752_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","volume":"27","author":"NL Gonzales","year":"2017","unstructured":"Gonzales NL, Puwanant A, Lu A, Marks SM, Zivkovic SA (2017) Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord 27(3):266\u2013268","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2752_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","volume":"40","author":"E Chang","year":"2017","unstructured":"Chang E, Sabichi AL, Sada YH (2017) Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother 40(3):114\u2013116","journal-title":"J Immunother"},{"issue":"1","key":"2752_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.25141","volume":"54","author":"KH Lau","year":"2016","unstructured":"Lau KH, Kumar A, Yang IH, Nowak RJ (2016) Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 54(1):157\u2013161","journal-title":"Muscle Nerve"},{"issue":"7","key":"2752_CR16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T et al (2016) Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107(7):1055\u20131058","journal-title":"Cancer Sci"},{"key":"2752_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG (2017) Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82:128\u2013136","journal-title":"Eur J Cancer"},{"issue":"11","key":"2752_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134","journal-title":"Neurology"},{"key":"2752_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2017-0001","volume":"22","author":"KP Papadopoulos","year":"2017","unstructured":"Papadopoulos KP, Romero RS, Gonzales G, Dix JE, Lowy I, Fury M (2017) Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 22:1\u20133","journal-title":"Oncologist"},{"issue":"5","key":"2752_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1073274817729069","volume":"24","author":"K Richard","year":"2017","unstructured":"Richard K, Weslow J, Porcella SL, Nanjappa S (2017) A case report of steroid responsive nivolumab-induced encephalitis. Cancer Control 24(5):1\u20133","journal-title":"Cancer Control"},{"key":"2752_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","volume":"305","author":"MP Brown","year":"2017","unstructured":"Brown MP, Hissaria P, Hsieh AH, Kneebone C, Vallat W (2017) Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol 305:16\u201318","journal-title":"J Neuroimmunol"},{"issue":"2","key":"2752_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","volume":"27","author":"J Behling","year":"2017","unstructured":"Behling J, Kaes J, Munzel T, Grabbe S, Loquai C (2017) New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 27(2):155\u2013158","journal-title":"Melanoma Res"},{"issue":"4","key":"2752_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G Velasco De","year":"2017","unstructured":"De Velasco G, Je Y, Bosse D, Awad MM, Ott PA, Moreira RB et al (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5(4):312\u2013318","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2752_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"8","key":"2752_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","volume":"73","author":"TJ Williams","year":"2016","unstructured":"Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, Le DT et al (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73(8):928\u2013933","journal-title":"JAMA Neurol"},{"issue":"11","key":"2752_CR26","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/brain\/aww225","volume":"139","author":"LM Yshii","year":"2016","unstructured":"Yshii LM, Gebauer CM, Pignolet B, Maure E, Queriault C, Pierau M et al (2016) CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 139(11):2923\u20132934","journal-title":"Brain"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-2752-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T01:54:00Z","timestamp":1547430840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-2752-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,13]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2752"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-2752-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,13]]},"assertion":[{"value":"7 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This case study received an approval from the Head of Institutional Review Board (Helsinki Committee) of Rabin Medical Center, Petah Tikva, Israel. This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Israeli regulations do not require consent for case report or case series, provided that they are anonymous. This manuscript is a retrospective study, does not contain clinical studies and the data in this case series do not disclose the identities of the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}